39 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Cd28tm1Mak/Cd28+ Cd5tm1Cgn/Cd5tm1Cgn either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP)	abnormal T cell clonal deletion	J:110925
Cd28tm1Mak/Cd28tm1Mak Cd5tm1Cgn/Cd5+ either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP)	abnormal T cell clonal deletion	J:110925
Cd28tm1Mak/Cd28tm1Mak Cd5tm1Cgn/Cd5tm1Cgn either: (involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6) or (involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * DBA/1 * LP)	abnormal T cell clonal deletion	J:110925
	increased CD4-positive, alpha-beta T cell number	J:110925
	increased CD8-positive, alpha-beta T cell number	J:110925
Cd28tm1Mak/Cd28tm1Mak Cd40lgtm1Flv/Cd40lgtm1Flv NOD.Cg-Cd40lgtm1Flv Cd28tm1Mak	decreased regulatory T cell number	J:93421
	increased susceptibility to autoimmune diabetes	J:93421
	insulitis	J:93421
Cd28tm1Mak/Cd28tm1Mak Ndfip1Gt(RRD002)Byg/Ndfip1Gt(RRD002)Byg involves: 129P2/OlaHsd * 129S2/SvPas	abnormal esophageal epithelium morphology	J:205692
	esophageal inflammation	J:205692
	increased eosinophil cell number	J:205692
	increased interleukin-2 secretion	J:205692
	increased interleukin-4 secretion	J:205692
Cd28tm1Mak/Cd28tm1Mak Rc3h1san/Rc3h1+ involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu	decreased lymphoma incidence	J:189087
	increased T cell derived lymphoma incidence	J:189087
Cd28tm1Mak/Cd28tm1Mak Stat6tm1Gru/Stat6tm1Gru C.129S2(B6)-Cd28tm1Mak Stat6tm1Gru	increased susceptibility to parasitic infection	J:90987
Cd28tm1Mak/Cd28tm1Mak Tg(Cd4-cre)1Cwi/? Traf6tm2Ywc/Traf6tm2Ywc involves: 129S2/SvPas * C57BL/6 * DBA/2	decreased interleukin-2 secretion	J:130882
	decreased T cell proliferation	J:130882
	increased activated T cell number	J:130882
	increased memory T cell number	J:130882
Cd28tm1Mak/Cd28tm1Mak Tg(H2-K-Cd86)7All/0 involves: BALB/c * C57BL/6 * CBA	abnormal T cell differentiation	J:112266
Cd28tm1Mak/Cd28tm1Mak Tg(TcrLCMV)327Sdz/0 involves: 129S2/SvPas * C57BL/6 * DBA/2	abnormal T cell anergy	J:123989
	decreased cytotoxic T cell cytolysis	J:123989
	decreased splenocyte proliferation	J:123989
	decreased T cell proliferation	J:123989
Cd28tm1Mak/Cd28tm1Mak Tnfsf9tm1Thw/Tnfsf9tm1Thw involves: 129 * 129S2/SvPas * C57BL/6	abnormal cytotoxic T cell physiology	J:76373
	increased length of allograft survival	J:76373
Cd28tm1Mak/Cd28tm1Mak Tnfsf14tm1Kpf/Tnfsf14tm1Kpf involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6	increased length of allograft survival	J:77250
Cd28tm1Pjl/Cd28tm1Pjl Tg(DO11.10)10Dlo/0 involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6	abnormal T cell activation	J:25536
	abnormal T cell proliferation	J:25536
	abnormal thymocyte activation	J:25536
	decreased interleukin-2 secretion	J:25536
Cd28tm1Pjl/Cd28tm1Pjl Tg(H2-K-Cd86)27All/0 involves: 129P2/OlaHsd * C57BL/6 * CBA	decreased B cell number	J:112475
Cd28tm1Pjl/Cd28tm1Pjl Tnfrsf9tm1Byk/Tnfrsf9tm1Byk either: B6.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk or C.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk	abnormal class switch recombination	J:83722
	abnormal cytotoxic T cell physiology	J:83722
	decreased IgG1 level	J:83722
	decreased IgG2a level	J:83722
	decreased IgM level	J:83722
	decreased interleukin-12 secretion	J:83722
	decreased splenocyte proliferation	J:83722
	decreased susceptibility to type IV hypersensitivity reaction	J:83722
Cd28tm1Shr/Cd28tm1Shr Ctla4tm1Shr/Ctla4+ C.129S4-Cd28tm1Shr Ctla4tm1Shr	abnormal CD8-positive, alpha beta T cell morphology	J:125259
	increased susceptibility to autoimmune disorder	J:125259
Cd28tm1Shr/Cd28tm1Shr Ctla4tm1Shr/Ctla4tm1Shr C.129S4-Cd28tm1Shr Ctla4tm1Shr	abnormal interferon level	J:68642
	abnormal interleukin secretion	J:68642
	decreased CD4-positive, alpha-beta T cell number	J:68642
	decreased T cell proliferation	J:68642
	increased length of allograft survival	J:68642